Skeletal cell model to screen anti-diabetic compounds
US7052910B2 · kind B2 · utility
0Cited by
1References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 26, 2001 |
| Grant date | May 30, 2006 |
| Priority date | — |
| Expiry date | Oct 26, 2021 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/042
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to the development of insulin resistant skeletal muscle cell culture model useful for the screening of compounds that enhance insulin receptor (IR) and insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation required against type II diabetes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.